Future of Plaque Psoriasis

EP: 1.Overview of Plaque Psoriasis and Impact on Quality of Life

EP: 2.Burden of Plaque Psoriasis and Available Options for the Treatment of Plaque Psoriasis

EP: 3.Mechanism of Action of Biologics Used in Plaque Psoriasis

EP: 4.Experience with Biologics Treating Plaque Psoriasis

EP: 5.Selecting Biologics for Patients With Plaque Psoriasis

EP: 6.Switching Biologics in Patients With Plaque Psoriasis

EP: 7.Recent Approval of Deucravacitinib for Patients With Plaque Psoriasis

EP: 8.Other Treatment Options for Patients With Plaque Psoriasis

EP: 9.Plaque Psoriasis: Unmet Needs

EP: 10.Patient Referrals in Plaque Psoriasis

EP: 11.Physician Assistants and Their Role in Treatment of Plaque Psoriasis

EP: 12.Access to Medication for Plaque Psoriasis and Impact of Biosimilars

EP: 13.Impact of COVID-19 Pandemic on Patients With Plaque Psoriasis

EP: 14.Importance of Clinical Trials and Patient Experience in Plaque Psoriasis

Now Viewing

EP: 15.Future of Plaque Psoriasis

Jerry Bagel, MD, MS: What do you see as the future of psoriatic disease treatment, and what are some of the most anticipated developments in the field?

Alexa Hetzel, MS, PA-C: We talk about this all the time. We’re always searching for the cure. We’d always like to have everybody be 100% cured of their psoriasis, but we just did a clinical study and we’re going to be able to skin sample some of these patients to know which biologic, or medication, is going to work specifically for them based on their skin DNA. We have this great TYK2, deucravacitinib, which is exciting for patients. We also have a new IL-17 coming out, bimekizumab. We have great options.

Jerry Bagel, MD, MS: The pharmacogenetics will increase the frequency of us being able to get it right the first time. It’s not going to change the efficacy of these drugs, but it will change how we’re going to write because we can determine things, like if you’ll respond to IL-23 the best, and be 90% certain of how that goes.

As far as development, under the National Psoriasis Foundation, I was part of the study article about the treatment to target where our goal is that everybody should have 1% or less body surface area. Yes, to find a cure would be great. National Psoriasis Foundation is spending $4.5 million a year on research to find that goal. I will say it’s a lot easier to treat psoriasis in 2022 than it was in 1982, 1992, 2002, or even in 2012.

With that, thank you very much, Alexa, for this insightful discussion. Thank you to our audience for watching this HCPLive® presentation. We hope you found this Peers & Perspectives® discussion to be useful and informative.

Transcript Edited for Clarity